Is Eli Lilly Stock Going to $900? 1 Wall Street Analyst Thinks So.

Core Viewpoint - An analyst from BMO Capital has reduced the price target for Eli Lilly's stock despite positive news regarding its pipeline drug, indicating a complex market sentiment towards the company [1][2]. Company Summary - The new price target for Eli Lilly is set at $900 per share, reflecting a decrease of$110 from the previous assessment, while the analyst maintains an outperform recommendation [2]. - The analyst expressed optimism about Eli Lilly's obesity drug, Zepbound, which is reportedly outperforming Novo Nordisk's Wegovy, the only other FDA-approved GLP-1 treatment for weight loss [3][4]. - Concerns were raised regarding the broader macroeconomic environment, suggesting that economic pressures are impacting the healthcare sector, making Eli Lilly vulnerable [3]. Industry Summary - The pharmaceutical sector is viewed as more resilient compared to other industries amid a volatile global macroeconomy, as many drugs, including obesity treatments, are considered essential for patients [5]. - The ongoing trade war is expected to contribute to economic instability, but pharmaceutical companies like Eli Lilly are better insulated from these pressures [5].